Clinical trials: T Cell Non-Hodgkin Lymphoma
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
The goal of this open, single-arm practical, phase II, clinical study is to evaluate the efficacy and safety of the mitoxantrone hydrochloride liposome injection-containing regimens in bridging therapies of CD19 CAR-T cells.
- Trial name
- NCT06220097
- Testing
- Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Peripheral T Cell Lymphoma
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
This is a Phase I, multicenter, non-randomized, open-label, dose-exploratory clinical study to evaluate the safety and tolerability of linperlisib combined with SHR2554 in the treatment of R/R PTCL, and to preliminary observe the…
- Trial name
- NCT06712173
- Testing
- linperlisib and SHR2554
- Volunteers
- 33 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Study of Photopheresis in the Treatment of Erythrodermic MF and SS
PROMPT: a study of photopheresis for the treatment of erythrodermic mycosis fungoides and Sézary syndrome For this study, the investigators invite patients suffering from erythrodermic mycosis fungoides (MF) and Sézary syndrome…
- Trial name
- PROMPT (NCT03563040)
- Testing
- Methoxsalen, THERAKOS CELLEX Photopheresis System
- Where
- Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
The goal of the clinical research study is to find the highest tolerable dose of nelarabine when given as a continuous infusion to patients with a lymphoid malignancy that has not responded to, or has come back after treatment…
- Trial name
- NCT01094860
- Testing
- Nelarabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
NK/T Cell Lymphoma Nos
Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma
This is a single-arm, open-label, multicenter, phase 2 study designed to evaluate the efficacy and safety of brentuximab vedotin combined with PD-1 inhibitor tislelizumab in Chinese patients with relapsed/refractory CD30+ NK/CL.
- Trial name
- NCT05316246
- Testing
- Brentuximab Vedotin in Combination with Tislelizumab
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Cutaneous T-Cell Lymphoma (CTCL)
Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
The purpose of this study is to evaluate the efficacy, safety and tolerability of SHAPE administered topically to skin lesions in patients with early-stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT02213861
- Testing
- SHAPE
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- TetraLogic Pharmaceuticals
Peripheral T Cell Lymphoma
A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma
To evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with chidamide and azacitidine in the treatment of relapsed and refractory peripheral T-cell lymphoma
- Trial name
- NCT05495100
- Testing
- Mitoxantrone liposome、Chidamide、Azacitidine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
FIL_Dara-GDP is a phase II, open label, multicenter clinical trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL).
- Trial name
- NCT04251065
- Testing
- Daratumumab
- Where
- 7 sites in Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination.
- Trial name
- NCT05414500
- Testing
- Mogamulizumab, Brentuximab vedotin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Alabama at Birmingham
Lymphoma, T-Cell
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
This is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell…
- Trial name
- NCT06699771
- Testing
- GCC2005, Cyclophosphamide, Fludarabine
- Where
- 3 sites in South Korea
- Volunteers
- 53 people
- Sponsor
- GC Cell Corporation
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors
The clinical application and effect of ATG based myeloablative conditioning regimen after allogeneic hematopoietic stem cell transplantation in adult patients with aggressive T-cell lymphomas.
- Trial name
- HSCT (NCT02290132)
- Testing
- Rabbit Anti-human Thymocyte Globulin (ATG)
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma
- Trial name
- NCT06784726
- Testing
- Odronextamab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
T-cell Lymphoma, NK-Cell Lymphoma
T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
The designed study follows up on the previous one by the international T-cell project (Bellei et al,, 2012) and its purpose is to verify whether a prospective collection of data would permit access to more accurate information…
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Lymphoma Adults
- Trial name
- Tcell-Brazil (NCT03207789)
- Volunteers
- 500 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT05878184
- Testing
- SC291
- Where
- 10 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Sana Biotechnology
CD20 Positive, Chronic Lymphocytic Leukemia
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
This phase I trial studies the best dose and how well bendamustine works with standard chemotherapy (fludarabine, rituximab) in treating participants with lymphoid cancers undergoing stem cell transplant.
- Conditions
- CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT00880815
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma
The purpose of this study is to evaluate the efficacy and tolerability of L-asparaginase monotherapy as salvage treatment in patients with NK/T cell lymphoma
- Trial name
- NCT00854425
- Testing
- L-asparaginase
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Cutaneous T Cell Lymphoma
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management.
- Trial name
- REvMM2009 (NCT01132989)
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Florida Academic Dermatology Centers
Lung Cancer, Lymphoma
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: AMG 706 may stop the growth of cancer cells by blocking blood flow to the cancer or by blocking some of the enzymes needed for cell growth.
- Conditions
- Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00324597
- Testing
- gemcitabine hydrochloride, motesanib diphosphate, pharmacological study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Mycosis Fungoides
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
In this pilot study, pembrolizumab will be administered via DoseConnect in patient with relapsed or refractory cutaneous T-cell lymphoma to assess through pharmacodynamic assessment in the tumor tissue to assess if lymphatic…
- Trial name
- NCT04118868
- Testing
- Pembrolizumab administered using the Sofusa® DoseConnect™
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sorrento Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.